BioNexus Gene Lab Corp (BGLC)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Batam | 54,268 [1] | - | - | - |
| BD | 28,852 [1] | - | - | - |
| LK | 109,371 [1] | - | - | - |
| MA | 1,830,563 [1] | - | - | - |
| MV | 139,576 [1] | - | - | - |
| SG | 97,623 [1] | - | - | - |
| Revenue (including 16,109 and 7,737 of revenue from related parties for the three month period ended june 30, 2025 and 2024, respectively, and 32,179 and 41,823 of revenue from related parties for the six month period ended june 30, 2025 and 2024, respectively) | 2,260,253 | 2,137,075 | 2,630,376 | - |
| Cost of revenue (including 2,307 and 28,766 of cost of revenue from related parties for the three month period ended june 30, 2025 and 2024, respectively, and 2,307 and 105,980 of cost of revenue from related parties for the six month period ended june 30, 2025 and 2024, respectively) | 1,892,231 | 1,793,582 | 2,303,840 | - |
| Gross profit | 368,022 | 343,493 | 326,536 | - |
| Sales and marketing | 608,427 | - | - | - |
| Research and development | 12,557 | - | - | - |
| General and administrative (including 1,012 and nil of rental expenses to related party for the three month period ended june 30, 2025 and 2024, respectively, and 2,056 and nil of rental expenses to related party for the six month period ended june 30, 2025 and 2024, respectively) | 516,790 | - | 2,129,685 | - |
| Fair value loss on investments in equity securities | 51,002 | - | - | - |
| Provision for expected credit losses | - | - | - | - |
| Total operating expenses | 1,188,776 | -1,053,331 | - | - |
| Dividend income | 8,626 | 8,934 | - | - |
| Others | 77,566 | 29,251 | 465,527 | - |
| Interest income | 29,768 | 23,568 | - | - |
| Fair value gain on investments in equity securities | 23,742 | 4,514 | - | - |
| Reversal of expected credit losses | 69,759 | 25,153 | - | - |
| Gain on disposal of investments in equity securities | - | - | - | - |
| Total other income | 209,461 | 91,420 | - | - |
| (loss)/profit from operations | -611,293 | -618,418 | -1,337,622 | - |
| Finance costs | 4,879 | 4,909 | - | - |
| Interest expense, operating and nonoperating | - | - | 6,193 | - |
| (loss)/profit before tax | -616,172 | -623,327 | -1,343,815 | - |
| Tax expense | - | - | 1,555 | - |
| Net (loss)/profit attributable to common shareholders | -616,172 | -623,327 | -1,345,370 | 199,104 |
| Foreign currency translation gain/(loss) | 367,078 | - | - | - |
| Foreign currency translation gain/(loss) | - | 72,159 | 1,046,789 | 2,463 |
| Comprehensive (loss)/profit | -249,094 | -551,168 | -298,581 | 201,567 |
| Basic & diluted average shares | - | - | - | 17,667,663 |
| Basic & diluted eps | - | - | -0.017 | 0.011 |
| Earnings per share - basic and diluted | -0.343 | -0.035 | - | - |
| Weighted average number of common stocks outstanding, basic and diluted | 1,796,597 | 17,967,663 | - | - |